US · SKIN · MEDICAL - DEVICES
SkinHealth Systems Inc. (SKIN) intrinsic value and stock valuation
$11.77as of 2026-11-21 · Mkt cap 85.67M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
SkinHealth Systems Inc. DCF and intrinsic value
InvestorsCraft values SKIN with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from SKIN’s statements →
SkinHealth Systems Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2018–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $300.8M | $334.3M | $398M | $365.9M | $260.1M |
| Operating income | -$-20.8M | -$-67.77M | -$-130.92M | -$-25.84M | -$-39.93M |
| Net income | -$-9.52M | -$-29.1M | -$-100.12M | $44.2M | -$-378.76M |
| EPSd | -$-70.1K | -$-204.22K | -$-760.33K | $297.8K | -$-3.71M |
| Operating cash flow | $37.5M | $16.1M | $21.8M | -$-106.6M | -$-28.36M |
| Capital expenditure | -$-300K | -$-6.79M | -$-13.05M | -$-17.39M | -$-15.62M |
| Free cash flow | $37.2M | $9.34M | $8.7M | -$-123.99M | -$-43.98M |
| Total assets | $499.8M | $685.7M | $929.1M | $1B | $1.22B |
| Total debt | $378.7M | $568.2M | $752.3M | $751.8M | $746.4M |
| Net debt | $146M | $198.1M | $229.3M | $183.6M | -$-155.48M |
| Total equity | $61.1M | $51.8M | $59.4M | $167.1M | $302.3M |
| Cash and short-term investments | $232.7M | $370.1M | $523M | $568.2M | $901.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $300.8M | $334.3M | $398M | $365.9M | $260.1M |
| Cost of revenue | $104.4M | $152M | $242.9M | $117.1M | $81.6M |
| Gross profit | $196.4M | $182.3M | $155.1M | $248.8M | $178.5M |
| Research and development expenses | $5.63M | $6.3M | $10.1M | $8.44M | $8.2M |
| Selling, general and administrative expenses | $211.5M | $243.8M | $275.9M | $266.2M | $210.3M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $217.2M | $250.1M | $286M | $274.6M | $218.5M |
| Cost and expenses | $321.6M | $402.1M | $528.9M | $391.7M | $300M |
| Interest income | $8.95M | $16.6M | $23.2M | $9.18M | $40K |
| Interest expense | $19.3M | $10.4M | $13.7M | $13.4M | $11.8M |
| Depreciation and amortization | $25.4M | $29.5M | $34.7M | $22.9M | $17.9M |
| Ebitda | $38.7M | $10.3M | -$-53.56M | $81.6M | -$-350.93M |
| Operating income | -$-20.8M | -$-67.77M | -$-130.92M | -$-25.84M | -$-39.93M |
| Total other income/expenses, net | $14.9M | $38.2M | $29M | $71.2M | -$-340.71M |
| Income before tax | -$-5.94M | -$-29.55M | -$-101.89M | $45.3M | -$-380.64M |
| Income tax expense | $3.58M | -$-450K | -$-1.77M | $1.11M | -$-1.88M |
| Net income | -$-9.52M | -$-29.1M | -$-100.12M | $44.2M | -$-378.76M |
| Weighted average shares outstanding | $126.4M | $123.8M | $131.7M | $147.6M | $102.1M |
| Weighted average diluted shares outstanding | $135.8M | $142.5M | $131.7M | $148.5M | $102.1M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $232.7M | $370.1M | $523M | $568.2M | $901.9M |
| Net receivables | $23.4M | $28.5M | $55M | $77.8M | $51.4M |
| Inventory | $48M | $69.1M | $91.3M | $109.7M | $35.3M |
| Total current assets | $309.5M | $477.1M | $698.3M | $783.3M | $1B |
| Property, plant and equipment, net | $14.1M | $19.6M | $26.4M | $33.8M | $31.2M |
| Goodwill and intangible assets | $162.4M | $171M | $187.9M | $171M | $179.7M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $190.3M | $208.6M | $230.9M | $219.8M | $217.9M |
| Total assets | $499.8M | $685.7M | $929.1M | $1B | $1.22B |
| Accounts payable | $15.6M | $21.9M | $44.8M | $28.5M | $29.1M |
| Short-term debt | $129.1M | $5.15M | $4.6M | $4.96M | $3.71M |
| Deferred revenue | $0.00 | $2.38M | $450K | $0.00 | $0.00 |
| Total current liabilities | $186.3M | $68.2M | $115M | $71.7M | $76.4M |
| Long-term debt | $249.7M | $563M | $747.7M | $746.8M | $742.7M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $252.5M | $565.7M | $754.7M | $764.3M | $840.1M |
| Capital lease obligations | $9.24M | $16M | $13.9M | $17.7M | $16.5M |
| Total liabilities | $438.7M | $633.9M | $869.7M | $836M | $916.5M |
| Common stock | $10K | $10K | $10K | $10K | $20K |
| Retained earnings | -$-517.5M | -$-507.96M | -$-478.87M | -$-378.75M | -$-418.71M |
| Accumulated other comprehensive income (loss) | -$-1.4M | -$-6.95M | -$-3.04M | -$-4.53M | -$-1.26M |
| Total equity | $61.1M | $51.8M | $59.4M | $167.1M | $302.3M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $378.7M | $568.2M | $752.3M | $751.8M | $746.4M |
| Net debt | $146M | $198.1M | $229.3M | $183.6M | -$-155.48M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-9.5M | -$-29.1M | -$-100.12M | $44.4M | -$-375.11M |
| Depreciation and amortization | $20.8M | $33.7M | $34.7M | $22M | $21.1M |
| Stock-based compensation | $14.8M | $26.7M | $22.5M | $28.5M | $12.4M |
| Change in working capital | $10.4M | -$-27.39M | $23.4M | -$-140.28M | -$-18.66M |
| Accounts receivable | $8.59M | $20.8M | $12.9M | -$-32.02M | -$-31.01M |
| Inventory | $15.8M | -$-10.5M | $19.6M | -$-82.1M | -$-9.44M |
| Accounts payable | -$-7.2M | -$-43.78M | $15.8M | $1.61M | $10.5M |
| Net cash provided by operating activities | $37.5M | $16.1M | $21.8M | -$-106.6M | -$-28.36M |
| Investments in property, plant and equipment | -$-5.16M | -$-6.79M | -$-13.05M | -$-17.39M | -$-15.62M |
| Acquisitions, net | $0.00 | $0.00 | -$-18.46M | -$-1.48M | -$-22.9M |
| Net cash used for investing activities | -$-5.16M | -$-6.79M | -$-31.51M | -$-18.87M | -$-37.73M |
| Common stock issued | -$-1.57M | $0.00 | $0.00 | $0.00 | $938.4M |
| Common stock repurchased | $0.00 | -$-1.96M | -$-32.4M | -$-160M | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-174.9M | -$-158.34M | -$-37.45M | -$-205.24M | $959M |
| Net change in cash | -$-137.4M | -$-152.96M | -$-45.17M | -$-333.69M | $892.4M |
| Cash at end of period | $232.7M | $370.1M | $523M | $568.2M | $901.9M |
| Operating cash flow | $37.5M | $16.1M | $21.8M | -$-106.6M | -$-28.36M |
| Capital expenditure | -$-300K | -$-6.79M | -$-13.05M | -$-17.39M | -$-15.62M |
| Free cash flow | $37.2M | $9.34M | $8.7M | -$-123.99M | -$-43.98M |
Line items
Line items
Line items
About SkinHealth Systems Inc.
SkinHealth Systems Inc., a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions in the Americas, the Asia-Pacific, Europe, the Middle East, Africa, Canada, and Latin America. The company's flagship product is HydraFacial, which enhances the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. It also offers Syndeo devices, which are delivery systems that are designed to connect providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling and nanoneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive peptide solutions and take home sprays for treating scalp health. In addition, it operates the MyBeautyHealth mobile application for consumers to earn loyalty points and unlock savings, log skin concerns and receive personalized treatment plans, and find and connect with Hydrafacial providers, as well as offers boosters. The company was formerly known as The Beauty Health Company and changed its name to SkinHealth Systems Inc. in April 2026. The company was founded in 1997 and is headquartered in Long Beach, California.
- CEO
- Pedro Malha
- Employees
- 613
- Beta
- 1.08
Explore
Frequently asked questions
What is the intrinsic value of SkinHealth Systems Inc. (SKIN)?
SkinHealth Systems Inc. (SKIN) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is SKIN undervalued?
SKIN trades at a price of $11.77 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.